

Remarks

After entry of the above amendment, claims 1-3 and 150-187 will be pending in this application.

Claims 1-3 are original claims.

Claims 4-149 have been cancelled without prejudice.

New Claims 150-187 have been added without introducing new matter. Support for new claims can be found throughout the application and claims as originally filed. Many of the new claims are merely combining several of the original claims into one claim and/or to remove multiple dependencies.

The specification has been amended to add the "Cross Reference to related application" section showing that this application is claiming priority to an earlier US provisional application.

The specification has also been amended to correct an obvious typographic error. Support for changing "phenyl" to "heteroaryl" can be found in the paragraph starting on page 37, line 26 of the published PCT application. Here in the first sentence of the paragraph, Z is described as being heteroaryl. In the following sentence of the same paragraph, Z is further defined as being heteroaryl optionally substituted with 1 to 5 substituents selected from a list of generic groups. Then in the next sentence of the same paragraph, the typographic error occurs. Clearly, the subject matter of the paragraph is related to Z as being heteroaryl and substituents related thereto and not to Z being phenyl (the description of Z being phenyl directly precedes this paragraph, see page 37, lines 18 to 25).

It is respectfully submitted that no new matter has been added by way of this amendment. The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16, 1.17, and 1.492 as required by this paper to Deposit Account No. 50-1441.

Respectfully submitted,

Date: December 9, 2005

  
Lyle W. Spruce, Ph.D.  
Registration No. 53,631

Arena Pharmaceuticals, Inc.  
6166 Nancy Ridge Drive  
San Diego, CA 92121  
Telephone: (858) 453-7200 x1425  
Facsimile: (858) 677-0065